All News
Filter News
Found 26 articles
-
Revolo Biotherapeutics to Present at 3rd Annual Treg Directed Therapies Summit
5/14/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that Dr. Roly Foulkes, Chief Scientific Officer, will present information relating to the Company’s lead autoimmune and allergic disease drug candidates, ’1805 and ‘1104, during the 3rd Annual Treg Directed Therapies Summit
-
Revolo Biotherapeutics Announces Positive Data from Additional Phase 1 Clinical Trial of ‘1104, its Peptide Drug for Allergic Disease‘1104 was safe and well-tolerated without serious adverse events
5/4/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission in patients with autoimmune (‘1805 a protein drug) and allergic disease (‘1104 a peptide drug), announced today positive data from a multiple ascending dose (MAD) Phase 1 clinical trial evaluating the safety and tolerability of ‘1104, a first-in-class peptide for the treatment of allergic disease
-
Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture ‘1104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease
4/15/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO),
-
New Orleans-based Revolo Biotherapeutics, formerly known as Immune Regulation, rebranded to reflect its revolutionary scientific approach to dramatically alter the autoimmune and allergic disease treatment landscape.
-
Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases
3/5/2021
Immune Regulation today announced it is rebranding as Revolo Biotherapeutics (“Revolo Bio”). The new brand, which will be implemented immediately, comes ahead of the advancement of the Company’s drug candidates into five clinical programs, including four Phase 2 trials.